Gemina Completes $910,000 Convertible Note Financing

Gemina Laboratories Ltd., headquartered in Vancouver, BC, announced the successful closing of its non-brokered private placement, raising $910,000 through the issuance of unsecured convertible notes. This financing move follows the company's news release on February 22, 2024, detailing the terms of the Notes. Gemina specifies that the funds acquired will be allocated to general working capital and corporate purposes.

The securities issued in this private placement are subject to a four-month hold period expiring on July 19, 2024, among other restrictions under applicable securities laws beyond Canada. Importantly, no finder's fees or any form of compensation were paid in connection with this financing effort.

Gemina also highlighted that the securities involved have not been registered under the United States Securities Act of 1933 and will not be offered or sold in the United States without registration or specific exemptions. This initiative underlines Gemina's ongoing efforts to strengthen its financial position and advance its diagnostic and biosensor technologies.

Gemina Labs, led by CEO Brian Firth, is noted for its innovative approach to developing testing platforms for various pathogens, including COVID-19, tuberculosis, and influenza. The company emphasizes its commitment to delivering swift, accurate, and affordable diagnostic solutions.